马瑞波,杨大刚,孙诚谊,王众
MA Ruibo,YANG Dagang,SUN Chengyi,WANG Zong (Department of Hepatobiliary Surgery

• 1:贵阳医学院附院肝胆外科

摘要(Abstract)：

目的:探讨细胞周期检测点启动DNA损伤修复的主要激酶Chk1蛋白在肝非肿瘤组织和原发性肝癌组织中的表达差异、以及与临床病理特征之间的关系。方法:应用免疫组织化学法检测15例肝非肿瘤组织(其中正常肝组织7例、肝硬化组织8例)和41例原发性肝癌组织Chk1蛋白的表达。结果:Chk1蛋白在原发性肝癌组织中表达阳性率为73.2%,在肝非肿瘤组织中表达阳性率为26.7%差异有统计学意义(P<0.05);Chk1蛋白在不同分化程度的原发性肝癌患者中的表达有差异,有统计学意义(P<0.05)。结论:Chk1在原发性肝癌中高表达可能与原发性肝癌的发生、发展有关。
Objective: To investigate the expression difference of Chk1 protien in primary liver cancer and non-tumor liver tissue,and to explore the probable relationship between its expression and clinicopathologic features of liver cancer.Methods: Immunohistochemistry was applied to detect the expressions of Chk1 in 15 cases with liver non-tumor tissue(7 cases with normal liver tissue,8 cases with cirrhosis tissue) and 41 cases with primary liver cancer with various differentiation degrees.Results: The positive expression rate of Chk1 in primary liver cancer(73.2%) was higher than that of non-tumor liver tissue(26.7%)(P<0.05).Significant differences were found in Chk1 expressions among primary liver cancer with various differentiation degrees(P<0.05).Conclusions: The high expression level of Chk1 in primary liver cancer indicates that Chk1 may be related to genesis and progression of primary liver cancer.

关键词(KeyWords)： 肝肿瘤;癌;细胞周期;免疫组织化学
liver neoplasms;carcinoma;cell cycle;immnohistochemistry

Abstract:

Keywords:

基金项目(Foundation): 贵州省科技厅基金资助项目(E2008-21)

作者(Author): 马瑞波,杨大刚,孙诚谊,王众
MA Ruibo,YANG Dagang,SUN Chengyi,WANG Zong (Department of Hepatobiliary Surgery

DOI: 10.19367/j.cnki.1000-2707.2012.05.008

参考文献(References)：

• [1]Studach L,Wang WH,Weber G,et al.Polo-like kinase 1activated by the hepatitis B virus X protein attenuates both theDNA damage checkpoint and DNA repair resulting in par-tial polyploidy[J].The Journal of Biological Chemistry,2010(39):30282-30293.
• [2]Gina Chun,Dongsoon Bae,Kristen Nickens,et al.Polo-like kinase 1 enhances survival and mutagenesis aftergenotoxic stress in normal cells through cell cycle check-point bypass[J].Carcinogenesis,2010(5):785–793.
• [3]Bartek J,Lukas J.Chk1 and Chk2 kinases in checkpointcontrol and cancer[J].Cancer Cell,2003(5):421-429.
• [4]Wong CF,Guminski A,Ssunders NA,et al.Exploitingnovel cell cycle targets in the development of anticancer a-gent[J].Curr Cancer Drug Targets,2005(2):85-102.
• [5]高庆蕾,叶飞,谢大兴,等.灭活细胞周期检测点激酶增强乳腺癌细胞放疗敏感性[J].中国妇幼保健,2008(23):4026-4028.
• [6]Matsumoto K,Nagahara T,Okano J,et al.The growthinhibition of hepatocellular and cholangiocellular carcino-ma cells by gemcitabine and the roles of extracellular sig-nal-regulated and checkpoint kinases[J].Oncol Rep,2008(4):863-872.
• [7]Bartek J,Lukas J.Chk1 and Chk2 kinases in check-point control and cancer[J].Cancer Cell,2003(5):421-429.
• [8]马全富,黄晓园,高庆蕾,等.Chk1/2和Plk1蛋白在子宫内膜癌中的表达[J].肿瘤防治研究,2008(6):424-426.
• [9]Tort F,Hernandez S,Bea S,et al.CHK2-decreased pro-tein expression and infrequent genetic alterations mainlyoccur in aggressive types of non-Hodgkin lymphomas[J].Blood,2002(13):4602-4608.
• [10]王玉祥,祝淑钗,王鑫,等.CHK1和CHK2在食管癌组织中的表达[J].肿瘤防治研究,2006(3):171-174.
• [11]Frederick A Derheimer,Heather M O’Hagan,HeatherM.Krueger,et al.RPA and ATR link transcriptionalstress to p53[J].Cell Biology,2007(31):12778-12783.

文章评论(Comment)：